Withdrawal due to disease worsening · Patients with active Crohn's disease
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).
2 findings from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI < 150) · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 9 mg probably leads to lower withdrawal due to disease worsening compared with mesalamine (moderate certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI < 150) · Patients with active Crohn's disease
Budesonide 9 mg probably leads to higher clinical improvement (decrease in CDAI > 100 or total CDAI < 150) ‐… compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (low certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Pain intensity various scales short‐term · patients with LBP
1 finding from 1 review
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Short‐term · patients with LBP
1 finding from 1 review
Function (higher scores mean more disability) ‐ Long‐term · patients with LBP
1 finding from 1 review
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
Pain intensity various scales short‐term · patients with LBP
1 finding from 1 review